Sign Up Today and Learn More About Pathios Therapeutics Stock

Invest in or calculate the value of your shares in Pathios Therapeutics or other pre-IPO companies through EquityZen's platform.

Get Started

Pathios Therapeutics Stock

Pathios Therapeutics is a biotech company focused on the development of therapies for autoimmune diseases and cancer.

About Pathios Therapeutics Stock

Founded

2017

Pathios Therapeutics is a biotech company focused on the development of therapies for autoimmune diseases and cancer. Pathios Therapeutics concentrates on the development of small molecule inhibitors targeting the pH-sensing G protein-coupled receptor GPR65. These inhibitors aim to counteract the immunosuppressive polarization of immune cells, such as tumor-associated macrophages, mediated by GPR65. This polarization is stimulated by the acidic tumor microenvironment commonly found in various cancers.

Pathios Therapeutics Management

Leadership team at Pathios Therapeutics

Co-Founder

Alan Naylor

Co-Founder

Tom McCarthy

Locked Features

Join now and verify your accreditation status to gain access to:

  • Pathios Therapeutics current valuation
  • Pathios Therapeutics stock price
  • Available deals in Pathios Therapeutics and all other companies
  • Deal offering documents
  • EquityZen's proprietary data and insights, including
    • Cap tables, which include funding history by Share Class and Liquidity Preferences
    • Company Highlights
    • Business Model
    • Risk Factors
Join Now

How to invest in Pathios Therapeutics stock?

Accredited investors can buy pre-IPO stock in companies like Pathios Therapeutics through EquityZen funds. These investments are made available by existing Pathios Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.

How to sell Pathios Therapeutics stock?

Shareholders can sell their Pathios Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 310K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.

If I invest, how do I exit my investment?

There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.

Why choose EquityZen?

Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 41K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."